Skip to content
Clinical Trials – home

Groupe Sos Sante

Research site

France 175 Rue Marechal Foch, 71200 Le Creusot, France

  • Type 2 diabetes mellitus · Obesity · Arteriosclerosis
  • Adult patients

About Specializations

Groupe Sos Sante in Le Creusot, France specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Obesity, Arteriosclerosis, Chronic kidney disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Disease Research

The Diabetologie department at Groupe Sos Sante is dedicated to advancing care for patients with Cardiovascular Diseases, including atherosclerotic disease, heart failure risk, and related outcomes in individuals with diabetes and obesity.

  • Evaluation of combination therapies aimed at lowering heart failure events and cardiovascular death
  • Assessment of novel GLP‑1 based agents for reducing major cardiovascular morbidity and mortality
  • Comparative safety analysis of tirzepatide versus dulaglutide on major adverse cardiovascular events
  • Investigation of cardiovascular benefits in overweight or obese patients with type 2 diabetes

The site’s investigators collaborate closely with local cardiology units to bring innovative treatment options to the community.

Metabolic and Obesity Research

Focused on Nutritional and Metabolic Diseases, the clinic conducts studies that target weight management, glycaemic control, and overall metabolic health in adults with type 2 diabetes and excess body weight.

  • Trials testing the efficacy of new agents for sustained weight loss in obesity
  • Evaluation of therapies that improve glycaemic outcomes while supporting weight reduction
  • Exploration of treatment strategies that address both diabetes and obesity concurrently
  • Research on lifestyle‑integrated approaches to enhance metabolic wellness

Located in Le Creusot, the centre leverages its hospital setting to provide comprehensive support for participants throughout the studies.

Integrated Cardiometabolic Studies

By bridging Cardiovascular and Metabolic research, Groupe Sos Sante investigates complex conditions such as chronic kidney disease and painful diabetic peripheral neuropathy that often accompany diabetes and obesity.

  • Examination of therapies that slow chronic kidney disease progression in diabetic patients
  • Assessment of novel compounds for reducing neuropathic pain in type 2 diabetes
  • Studies on surrogate markers linking metabolic health to cardiovascular outcomes
  • Integrated analyses of weight, kidney function, and heart failure risk

Four dedicated investigators lead these multidisciplinary projects, fostering collaboration across specialties to improve patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
175 Rue Marechal Foch71200 Le CreusotFrance
Recruiting now
no trials
Conditions studied
6

More sites in Le CreusotFrance

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

5 clinical trials

Type 2 diabetes mellitus+3

Not recruiting

A study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Diabetic neuropathy+1

Not recruiting

Study of cagrilintide and semaglutide combination versus placebo in people with type 2 diabetes and painful diabetic peripheral neuropathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.